Skip to main content
SpringerLink
Log in

Salvage extended field or involved field nodal irradiation in 18F-fluorocholine PET/CT oligorecurrent nodal failures from prostate cancer

  • Original Article
  • Published:
European Journal of Nuclear Medicine and Molecular Imaging Aims and scope Submit manuscript

Abstract

Purpose

The concept of metastasis-directed therapy for nodal oligorecurrences with stereotactic body radiotherapy is increasingly accepted. Hence, the comparison between salvage extended field radiotherapy (s-EFRT) and salvage involved field radiotherapy (s-IFRT) in patients with 18F-fluorocholine (FCH) PET/CT+ nodal oligorecurrences from prostate cancer is worthy of investigation.

Methods

Patients with oligorecurrent nodes on FCH PET/CT treated with salvage radiotherapy between 2009 and 2017 in a single tertiary cancer centre were selected for this study. Patients treated with s-IFRT were compared with those treated with s-EFRT. Toxicities and times to failure (TTF) were compared between the two groups.

Results

The study included 62 patients with positive lymph nodes only who underwent FCH PET/CT for a rising PSA level after radical prostatectomy or radiotherapy. Of these patients, 35 had s-IFRT and 27 had s-EFRT. After a median follow-up of 41.8 months (range 5.9–108.1 months), no differences were observed in acute or late gastrointestinal and genitourinary toxicities of grade 2 or more between the two groups. The 3-year failure rates were 55.3% (95% CI 37.0–70.3%) in the s-IFRT group and 88.3% (95% CI 66.9–96.1%) in the s-EFRT group (p = 0.0094). In multivariate analysis of TTF, an interval of >5 years was significantly correlated with better outcomes (HR = 0.33, 95% CI 0.13–0.86, p = 0.023). There was a strong trend toward better outcomes with s-EFRT even after adjusting for concomitant androgen-deprivation therapy (HR = 0.38, 95% CI 0.12–1.27, p = 0.116).

Conclusion

FCH PET-positive node-targeted s-EFRT is feasible with low rates of toxicity and longer TTF, suggesting that oligorecurrent nodal disease diagnosed on FCH PET is unlikely.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Lepinoy A, Cochet A, Cueff A, Cormier L, Martin E, Maingon P, et al. Pattern of occult nodal relapse diagnosed with (18)F-fluoro-choline PET/CT in prostate cancer patients with biochemical failure after prostate-only radiotherapy. Radiother Oncol. 2014;111:120–5. https://doi.org/10.1016/j.radonc.2014.03.008.

    Article  PubMed  Google Scholar 

  2. Decaestecker K, De Meerleer G, Lambert B, Delrue L, Fonteyne V, Claeys T, et al. Repeated stereotactic body radiotherapy for oligometastatic prostate cancer recurrence. Radiat Oncol. 2014;9:135. https://doi.org/10.1186/1748-717X-9-135.

    Article  PubMed  PubMed Central  Google Scholar 

  3. Jereczek-Fossa BA, Fariselli L, Beltramo G, Catalano G, Serafini F, Garibaldi C, et al. Linac-based or robotic image-guided stereotactic radiotherapy for isolated lymph node recurrent prostate cancer. Radiother Oncol. 2009;93:14–7. https://doi.org/10.1016/j.radonc.2009.04.001.

    Article  PubMed  Google Scholar 

  4. Ost P, Bossi A, Decaestecker K, De Meerleer G, Giannarini G, Karnes RJ, et al. Metastasis-directed therapy of regional and distant recurrences after curative treatment of prostate cancer: a systematic review of the literature. Eur Urol. 2015;67:852–63. https://doi.org/10.1016/j.eururo.2014.09.004.

    Article  PubMed  Google Scholar 

  5. Ploussard G, Almeras C, Briganti A, Giannarini G, Hennequin C, Ost P, et al. Management of node only recurrence after primary local treatment for prostate cancer: a systematic review of the literature. J Urol. 2015;194:983–8. https://doi.org/10.1016/j.juro.2015.04.103.

    Article  PubMed  Google Scholar 

  6. Schick U, Jorcano S, Nouet P, Rouzaud M, Vees H, Zilli T, et al. Androgen deprivation and high-dose radiotherapy for oligometastatic prostate cancer patients with less than five regional and/or distant metastases. Acta Oncol. 2013;52:1622–8. https://doi.org/10.3109/0284186X.2013.764010.

    Article  CAS  PubMed  Google Scholar 

  7. Pasqualetti F, Panichi M, Sainato A, Matteucci F, Galli L, Cocuzza P, et al. [(18)F]Choline PET/CT and stereotactic body radiotherapy on treatment decision making of oligometastatic prostate cancer patients: preliminary results. Radiat Oncol. 2016;11:9. https://doi.org/10.1186/s13014-016-0586-x.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Ponti E, Ingrosso G, Carosi A, Di Murro L, Lancia A, Pietrasanta F, et al. Salvage stereotactic body radiotherapy for patients with prostate cancer with isolated lymph node metastasis: a single-center experience. Clin Genitourin Cancer. 2015;13:e279–84. https://doi.org/10.1016/j.clgc.2014.12.014.

    Article  PubMed  Google Scholar 

  9. Ingrosso G, Trippa F, Maranzano E, Carosi A, Ponti E, Arcidiacono F, et al. Stereotactic body radiotherapy in oligometastatic prostate cancer patients with isolated lymph nodes involvement: a two-institution experience. World J Urol. 2017;35:45–9. https://doi.org/10.1007/s00345-016-1860-0.

    Article  CAS  PubMed  Google Scholar 

  10. Beheshti M, Haim S, Zakavi R, Steinmair M, Waldenberger P, Kunit T, et al. Impact of 18F-choline PET/CT in prostate cancer patients with biochemical recurrence: influence of androgen deprivation therapy and correlation with PSA kinetics. J Nucl Med. 2013;54:833–40. https://doi.org/10.2967/jnumed.112.110148.

    Article  CAS  PubMed  Google Scholar 

  11. Cimitan M, Bortolus R, Morassut S, Canzonieri V, Garbeglio A, Baresic T, et al. [18F]fluorocholine PET/CT imaging for the detection of recurrent prostate cancer at PSA relapse: experience in 100 consecutive patients. Eur J Nucl Med Mol Imaging. 2006;33:1387–98. https://doi.org/10.1007/s00259-006-0150-2.

    Article  PubMed  Google Scholar 

  12. Picchio M, Messa C, Landoni C, Gianolli L, Sironi S, Brioschi M, et al. Value of [11C]choline-positron emission tomography for re-staging prostate cancer: a comparison with [18F]fluorodeoxyglucose-positron emission tomography. J Urol. 2003;169:1337–40. https://doi.org/10.1097/01.ju.0000056901.95996.43.

    Article  CAS  PubMed  Google Scholar 

  13. Schmid DT, John H, Zweifel R, Cservenyak T, Westera G, Goerres GW, et al. Fluorocholine PET/CT in patients with prostate cancer: initial experience. Radiology. 2005;235:623–8. https://doi.org/10.1148/radiol.2352040494.

    Article  PubMed  Google Scholar 

  14. Crehange G, Chen CP, Hsu CC, Kased N, Coakley FV, Kurhanewicz J, et al. Management of prostate cancer patients with lymph node involvement: a rapidly evolving paradigm. Cancer Treat Rev. 2012;38:956–67. https://doi.org/10.1016/j.ctrv.2012.05.005.

    Article  PubMed  PubMed Central  Google Scholar 

  15. Passoni NM, Suardi N, Abdollah F, Picchio M, Giovacchini G, Messa C, et al. Utility of [11C]choline PET/CT in guiding lesion-targeted salvage therapies in patients with prostate cancer recurrence localized to a single lymph node at imaging: results from a pathologically validated series. Urol Oncol. 2014;32:38 e9–16. https://doi.org/10.1016/j.urolonc.2013.03.006.

    Article  Google Scholar 

  16. Suardi N, Gandaglia G, Gallina A, Di Trapani E, Scattoni V, Vizziello D, et al. Long-term outcomes of salvage lymph node dissection for clinically recurrent prostate cancer: results of a single-institution series with a minimum follow-up of 5 years. Eur Urol. 2015;67:299–309. https://doi.org/10.1016/j.eururo.2014.02.011.

    Article  PubMed  Google Scholar 

  17. Herlemann A, Wenter V, Kretschmer A, Thierfelder KM, Bartenstein P, Faber C, et al. (68)Ga-PSMA positron emission tomography/computed tomography provides accurate staging of lymph node regions prior to lymph node dissection in patients with prostate cancer. Eur Urol. 2016;70:553–7. https://doi.org/10.1016/j.eururo.2015.12.051.

    Article  CAS  PubMed  Google Scholar 

  18. Hijazi S, Meller B, Leitsmann C, Strauss A, Meller J, Ritter CO, et al. Pelvic lymph node dissection for nodal oligometastatic prostate cancer detected by 68Ga-PSMA-positron emission tomography/computerized tomography. Prostate. 2015;75:1934–40. https://doi.org/10.1002/pros.23091.

    Article  CAS  PubMed  Google Scholar 

  19. Kitajima K, Murphy RC, Nathan MA, Froemming AT, Hagen CE, Takahashi N, et al. Detection of recurrent prostate cancer after radical prostatectomy: comparison of 11C-choline PET/CT with pelvic multiparametric MR imaging with endorectal coil. J Nucl Med. 2014;55:223–32. https://doi.org/10.2967/jnumed.113.123018.

    Article  CAS  PubMed  Google Scholar 

  20. Scattoni V, Picchio M, Suardi N, Messa C, Freschi M, Roscigno M, et al. Detection of lymph-node metastases with integrated [11C]choline PET/CT in patients with PSA failure after radical retropubic prostatectomy: results confirmed by open pelvic-retroperitoneal lymphadenectomy. Eur Urol. 2007;52:423–9. https://doi.org/10.1016/j.eururo.2007.03.032.

    Article  PubMed  Google Scholar 

  21. Afshar-Oromieh A, Zechmann CM, Malcher A, Eder M, Eisenhut M, Linhart HG, et al. Comparison of PET imaging with a (68)Ga-labelled PSMA ligand and (18)F-choline-based PET/CT for the diagnosis of recurrent prostate cancer. Eur J Nucl Med Mol Imaging. 2014;41:11–20. https://doi.org/10.1007/s00259-013-2525-5.

    Article  CAS  PubMed  Google Scholar 

  22. Casamassima F, Masi L, Menichelli C, Bonucci I, Casamassima E, Lazzeri M, et al. Efficacy of eradicative radiotherapy for limited nodal metastases detected with choline PET scan in prostate cancer patients. Tumori. 2011;97:49–55.

    Article  CAS  Google Scholar 

  23. Muacevic A, Kufeld M, Rist C, Wowra B, Stief C, Staehler M. Safety and feasibility of image-guided robotic radiosurgery for patients with limited bone metastases of prostate cancer. Urol Oncol. 2013;31:455–60. https://doi.org/10.1016/j.urolonc.2011.02.023.

    Article  PubMed  Google Scholar 

  24. Ost P, Reynders D, Decaestecker K, Fonteyne V, Lumen N, De Bruycker A, et al. Surveillance or metastasis-directed therapy for oligometastatic prostate cancer recurrence: a prospective, randomized, multicenter phase II trial. J Clin Oncol. 2018;36:446–53. https://doi.org/10.1200/JCO.2017.75.4853.

    Article  CAS  PubMed  Google Scholar 

  25. Guerrero Urbano T, Khoo V, Staffurth J, Norman A, Buffa F, Jackson A, et al. Intensity-modulated radiotherapy allows escalation of the radiation dose to the pelvic lymph nodes in patients with locally advanced prostate cancer: preliminary results of a phase I dose escalation study. Clin Oncol. 2010;22:236–44. https://doi.org/10.1016/j.clon.2010.01.005.

    Article  CAS  Google Scholar 

  26. Roach M 3rd, De Silvio M, Lawton C, Uhl V, Machtay M, Seider MJ, et al. Phase III trial comparing whole-pelvic versus prostate-only radiotherapy and neoadjuvant versus adjuvant combined androgen suppression: Radiation Therapy Oncology Group 9413. J Clin Oncol. 2003;21:1904–11. https://doi.org/10.1200/JCO.2003.05.004.

    Article  PubMed  Google Scholar 

Download references

Funding

None.

Author information

Authors and Affiliations

  1. Department of Radiation Oncology, University Hospital Jean Minjoz, 25000, Besançon, France

    Alexis Lépinoy

  2. Department of Nuclear Medicine, Unicancer-Georges François Leclerc Cancer Center, 21000, Dijon, France

    Yannick E. Silva & Alexandre Cochet

  3. Department of Radiation Oncology, Unicancer-Georges François Leclerc Cancer Center, 21000, Dijon, France

    Etienne Martin, Magali Quivrin & Gilles Créhange

  4. Department of Biostatistics, Unicancer-Georges François Leclerc Cancer Center, 21000, Dijon, France

    Aurélie Bertaut

  5. Department of Medical Physics and Radiation Oncology, Unicancer-Georges François Leclerc Cancer Center, 21000, Dijon, France

    Léone Aubignac

  6. Medical Imaging Group, IMAC CNRS FRE2005, University of Burgundy, Dijon, France

    Alexandre Cochet & Gilles Créhange

Authors
  1. Alexis Lépinoy
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Yannick E. Silva
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Etienne Martin
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Aurélie Bertaut
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Magali Quivrin
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Léone Aubignac
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Alexandre Cochet
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Gilles Créhange
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Gilles Créhange.

Ethics declarations

Conflicts of interest

None.

Ethical approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the principles of the 1964 Declaration of Helsinki and its later amendments or comparable ethical standards.

Informed consent

All the patients included in this study provided signed informed consent for their data to be used for research purposes.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Lépinoy, A., Silva, Y.E., Martin, E. et al. Salvage extended field or involved field nodal irradiation in 18F-fluorocholine PET/CT oligorecurrent nodal failures from prostate cancer. Eur J Nucl Med Mol Imaging 46, 40–48 (2019). https://doi.org/10.1007/s00259-018-4159-0

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00259-018-4159-0

Keywords

Search

Navigation